Geode Capital Management’s Anebulo Pharmaceuticals ANEB Stock Holding History

Geode Capital Management’s Portfolio ANEB Stock Details ANEB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-160,760	Closed	-$162K	–	4518
2025 Q4	$162K	Sell	160,760 -13,348	-8%	-$30.5K	﹤0.01%	3980
2025 Q3	$436K	Sell	174,108 -31,612	-15%	-$74.4K	﹤0.01%	3673
2025 Q2	$296K	Buy	205,720 +302	+0.1%	+$344	﹤0.01%	3739
2025 Q1	$267K	Buy	205,418 +114,077	+125%	+$168K	﹤0.01%	3754
2024 Q4	$153K	Buy	91,341 +3,551	+4%	+$5.85K	﹤0.01%	3975
2024 Q3	$169K	Buy	87,790 +36,482	+71%	+$77.8K	﹤0.01%	3958
2024 Q2	$140K	Buy	51,308 +28,531	+125%	+$72.4K	﹤0.01%	4036
2024 Q1	$65.4K	Buy	+22,777	New	+$58.6K	﹤0.01%	4264

Geode Capital Management's ANEB Position: Q1 2026 in Review

Geode Capital Management sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2026, closing a stake of 160,760 shares — an estimated $162K sold.

Geode Capital Management first reported a position in ANEB in Q1 2024 and held it in 8 quarters. The position peaked at $436K in Q3 2025. 0 funds tracked by Wall St. Rank hold ANEB as of Q1 2026.

Geode Capital Management reported no remaining Anebulo Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Geode Capital Management sold 160,760 Anebulo Pharmaceuticals shares in Q1 2026, an estimated $162K.
Geode Capital Management first reported a position in Anebulo Pharmaceuticals in Q1 2024 and held it in 8 quarters.
Geode Capital Management's Anebulo Pharmaceuticals position peaked at $436K in Q3 2025.
0 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.